Switch theme
Sign up to access all valuation multiples
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
2018
120
LTM Revenue n/a
LTM EBITDA n/a
$109M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Celularity has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Celularity achieved revenue of $22.8M and an EBITDA of -$184M.
Celularity expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Celularity valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $18.0M | $22.8M | XXX | XXX | XXX |
| Gross Profit | $11.7M | -$1.7M | XXX | XXX | XXX |
| Gross Margin | 65% | -7% | XXX | XXX | XXX |
| EBITDA | $23.6M | -$184M | XXX | XXX | XXX |
| EBITDA Margin | 132% | -808% | XXX | XXX | XXX |
| Net Profit | -$100M | $14.2M | XXX | XXX | XXX |
| Net Margin | -557% | 62% | XXX | XXX | XXX |
| Net Debt | n/a | $23.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Celularity's stock price is $2.
Celularity has current market cap of $40.2M, and EV of $109M.
See Celularity trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $109M | $40.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Celularity has market cap of $40.2M and EV of $109M.
Celularity's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Celularity's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Celularity and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $109M | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | -0.6x | XXX | XXX | XXX |
| P/E | -0.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCelularity's NTM/LTM revenue growth is n/a
Celularity's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Celularity's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Celularity's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Celularity and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 27% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -808% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -878% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 134% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 366% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celularity acquired XXX companies to date.
Last acquisition by Celularity was XXXXXXXX, XXXXX XXXXX XXXXXX . Celularity acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Celularity founded? | Celularity was founded in 2018. |
| Where is Celularity headquartered? | Celularity is headquartered in United States of America. |
| How many employees does Celularity have? | As of today, Celularity has 120 employees. |
| Who is the CEO of Celularity? | Celularity's CEO is Dr. Robert J. Hariri, M.D.,PhD. |
| Is Celularity publicy listed? | Yes, Celularity is a public company listed on NAS. |
| What is the stock symbol of Celularity? | Celularity trades under CELU ticker. |
| When did Celularity go public? | Celularity went public in 2021. |
| Who are competitors of Celularity? | Similar companies to Celularity include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Celularity? | Celularity's current market cap is $40.2M |
| What is the current revenue growth of Celularity? | Celularity revenue growth between 2023 and 2024 was 27%. |
| Is Celularity profitable? | Yes, Celularity is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
